Dhinesh Selvaraju: A Step Closer to the ‘Ideal Anticoagulant’?
Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared a post on LinkedIn:
“A Step Closer to the ‘Ideal Anticoagulant’?
A significant advancement in thrombosis research is emerging from recent clinical evidence.
Bayer has reported encouraging Phase III results for its investigational oral Factor XIa inhibitor, Asundexian, evaluated in the OCEANIC-STROKE trial (2026) involving over 12,000 patients.
Key findings:
- Approximately 26% reduction in recurrent stroke risk
- No significant increase in major bleeding events
Why this matters ?
Despite their proven efficacy, current anticoagulants (DOACs, warfarin) are inherently limited by the risk of bleeding complications, often creating a therapeutic trade-off.
Asundexian introduces a novel mechanism:
- Selective inhibition of Factor XIa (intrinsic coagulation pathway)
- Targeting pathological thrombosis while preserving physiological hemostasis
Clinical significance:
- Reinforces the potential of Factor XI inhibition as a safer anticoagulation strategy
- Represents a promising shift in secondary stroke prevention
- Addresses a long-standing clinical challenge: Can thrombosis be prevented without increasing bleeding risk?
A paradigm shift in hemostasis:
This development reflects a broader transition in anticoagulant therapy:
From broad-spectrum anticoagulation to pathway-specific precision targeting
If validated through ongoing regulatory review, asundexian could redefine clinical practice in cerebrovascular risk management and set a new benchmark for next-generation anticoagulants.”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 16:43Scott Sutton: Community and Connection in Immune Thrombocytopenia
-
Sep 28, 2026, 16:24Pankti Solanki: ISBT Recognized JAMA as the 49th Human Blood Group System
-
Sep 28, 2026, 15:52Kassa Tameru: Antithrombotic Management in GI Bleeding and Elective Endoscopy
-
Sep 28, 2026, 15:51Chengappa Kavadichanda: How Do aPLs Change Over Time in Early Lupus?
-
Sep 28, 2026, 15:18Linda Shore-Lesserson: Celebrating 25 Years of PBM at the SABM Meeting
-
Sep 28, 2026, 14:45Access Real-Time Bleeding Disorder Guidelines with the New WFH Resource Hub – WFH
-
Sep 28, 2026, 14:44Subham Banerjee: When Routine Blood Grouping Hid a Rare Diagnosis
-
Sep 28, 2026, 14:41Francois Roubille: Can Low-Dose Colchicine Prevent Atrial Fibrillation After CABG?
-
Sep 28, 2026, 14:39William Aird: Gulliver’s Atlas – Mapping the Evolution of the Vertebrate Red Cell